论文部分内容阅读
近年来胰腺癌发病率越来越高,且预后较差,治疗颇为棘手。多数晚期胰腺癌患者的治疗以内科化疗为主,同时根据病情予放射治疗、同步放化疗、靶向治疗、免疫治疗及介入治疗等。传统化疗以吉西他滨、氟尿嘧啶、铂类为主,但疗效欠佳,纳米微粒型白蛋白结合型紫杉醇、激酶抑制剂(如厄洛替尼)、单克隆抗体(如尼妥珠单抗)等药物目前无显著阳性结果,免疫治疗方面相关临床研究结果不足,故寻求有效安全的内科治疗是目前晚期胰腺癌研究的主要攻点。本文就晚期胰腺癌的内科治疗现状作一综述。
In recent years, the incidence of pancreatic cancer is getting higher and higher, and the prognosis is poor, the treatment is quite difficult. Most patients with advanced pancreatic cancer treatment based chemotherapy, at the same time according to the condition of radiation therapy, concurrent chemoradiation, targeted therapy, immunotherapy and interventional therapy. Traditional chemotherapy with gemcitabine, fluorouracil, platinum-based, but poor efficacy, nano-particle albumin-bound paclitaxel, kinase inhibitors (such as erlotinib), monoclonal antibodies (such as nimotuzumab) and other drugs There is no significant positive results, immunotherapy related clinical research results are insufficient, so seeking effective and safe medical treatment is currently the main research point of the late pancreatic cancer. This article reviews the current status of medical treatment of advanced pancreatic cancer.